Bill > A07920

This bill requires insurance carriers and health plans to provide coverage for abuse-deterrent opioid medications, specifically mandating that they include at least one abuse-deterrent opioid analgesic drug product per active ingredient on their formulary. The bill ensures that cost-sharing for these medications (both brand name and generic) does not exceed the lowest cost-sharing level applied to non-abuse deterrent opioid drugs. Insurance providers are prohibited from increasing patient costs or creating disincentives to comply with this requirement. Additionally, prior authorization requirements cannot mandate the use of non-abuse deterrent opioid medications before accessing abuse-deterrent versions. The bill defines "abuse-deterrent opioid analgesic drug products" as medications approved by the FDA with labeling that indicates properties expected to deter or reduce drug abuse. These provisions aim to improve patient access to medications designed to combat opioid abuse by making abuse-deterrent technologies more affordable and accessible. The law will take effect 120 days after becoming law and will apply to all insurance policies issued, renewed, or modified after that date.

Business and Industry

https://www.nysenate.gov/legislation/bills/2025/A7920